Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes
暂无分享,去创建一个
[1] K. Sanderson,et al. Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia , 2017, Applied Health Economics and Health Policy.
[2] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[3] K. Sanderson,et al. Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model , 2016, PharmacoEconomics - Open.
[4] Sheri D Schully,et al. A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation , 2016, Genetics in Medicine.
[5] J. Ioannidis,et al. Clinical Genomics: From Pathogenicity Claims to Quantitative Risk Estimates. , 2016, JAMA.
[6] G. Henderson,et al. The Promise and Peril of Genomic Screening in the General Population , 2015, Genetics in Medicine.
[7] E. Wood,et al. Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron) , 2015, BMJ Open.
[8] G. Palomaki,et al. The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates , 2015, Genetics in Medicine.
[9] V. Heinemann,et al. Economic evaluation of genetic screening for Lynch syndrome in Germany , 2015, Genetics in Medicine.
[10] D. English,et al. Natural history of HFE simple heterozygosity for C282Y and H63D: A prospective 12‐year study , 2014, Journal of gastroenterology and hepatology.
[11] D. Swinkels,et al. Key-interventions derived from three evidence based guidelines for management and follow-up of patients with HFE haemochromatosis , 2014, BMC Health Services Research.
[12] I. Frayling,et al. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. , 2014, Health technology assessment.
[13] S. Leitman. Hemochromatosis: the new blood donor. , 2013, Hematology. American Society of Hematology. Education Program.
[14] Robert C. Green,et al. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium , 2013, Genetics in Medicine.
[15] B. Knoppers,et al. Recommendations for returning genomic incidental findings? We need to talk! , 2013, Genetics in Medicine.
[16] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[17] Elizabeth M Webber,et al. Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies , 2013, Genetics in Medicine.
[18] P. Romundstad,et al. Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study , 2013, Scandinavian journal of gastroenterology.
[19] Marylyn D. Ritchie,et al. Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network , 2012, Genetics in Medicine.
[20] M. Hulihan,et al. Iron overload: what is the role of public health? , 2011, American journal of preventive medicine.
[21] A. Morabia. Re: "The emergence of translational epidemiology: from scientific discovery to population health impact". , 2011, American journal of epidemiology.
[22] D. Gertig,et al. HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 μg/L are at low risk of hemochromatosis , 2010, Hepatology.
[23] J. Barton,et al. How I treat hemochromatosis. , 2010, Blood.
[24] E. Renard,et al. The Southern French registry of genetic hemochromatosis: a tool for determining clinical prevalence of the disorder and genotype penetrance , 2010, Haematologica.
[25] D. Petitti. Hereditary hemochromatosis: population screening for gene mutations , 2009 .
[26] John P. A. Ioannidis,et al. Human Genome Epidemiology , 2009 .
[27] P. Adams. The Natural History of Untreated HFE-Related Hemochromatosis , 2009, Acta Haematologica.
[28] M. Khoury,et al. Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics , 2009, Public Health Genomics.
[29] K. Kowdley,et al. HFE-associated hereditary hemochromatosis , 2009, Genetics in Medicine.
[30] W. Rogowski. The Cost-Effectiveness of Screening for Hereditary Hemochromatosis in Germany: A Remodeling Study , 2009, Medical decision making : an international journal of the Society for Medical Decision Making.
[31] J. Pankow,et al. HFE C282Y Homozygosity Is Associated With Lower Total and Low-Density Lipoprotein Cholesterol: The Hemochromatosis and Iron Overload Screening Study , 2009, Circulation. Cardiovascular genetics.
[32] J. Olynyk,et al. Clinical penetrance of C282Y homozygous HFE hemochromatosis , 2008, Expert review of hematology.
[33] H. Bonkovsky,et al. Hereditary Hemochromatosis: Time for Targeted Screening , 2008, Annals of Internal Medicine.
[34] J. Pankow,et al. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. , 2008, Translational research : the journal of laboratory and clinical medicine.
[35] V. Felitti,et al. Response: Screening for treatable disease is better than just screening for hemochromatosis , 2008 .
[36] B. Nordestgaard,et al. Hemochromatosis genotypes and risk of 31 disease endpoints: Meta‐analyses including 66,000 cases and 226,000 controls , 2007, Hepatology.
[37] K. Hveem,et al. Penetrance of the C28Y/C282Y genotype of the HFE gene , 2007, Scandinavian journal of gastroenterology.
[38] B. Yawn,et al. Screening for Hemochromatosis: Recommendation Statement , 2006, Annals of Internal Medicine.
[39] E. Harris,et al. Screening for Hereditary Hemochromatosis: A Systematic Review for the U.S. Preventive Services Task Force , 2006, Annals of Internal Medicine.
[40] D. Reboussin,et al. Liver diseases in the hemochromatosis and iron overload screening study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[41] M. Beaton,et al. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. , 2006, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[42] D. Hewett,et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. , 2006, Archives of internal medicine.
[43] R. Golub,et al. Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians , 2005, Annals of Internal Medicine.
[44] M. Aronson,et al. Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians , 2005, Annals of Internal Medicine.
[45] R. Williamson,et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis , 2005, The Lancet.
[46] E. Thomson,et al. Hemochromatosis and iron-overload screening in a racially diverse population. , 2005, The New England journal of medicine.
[47] B. Nordestgaard,et al. Hemochromatosis mutations in the general population: iron overload progression rate. , 2004, Blood.
[48] J. Beilby,et al. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. , 2004, Mayo Clinic proceedings.
[49] J. Koziol,et al. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA , 2002, The Lancet.
[50] K. Hveem,et al. Benefit of Population-based Screening for Phenotypic Hemochromatosis in Young Men , 2002, Scandinavian journal of gastroenterology.
[51] B. Nordestgaard,et al. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study , 2001, The Lancet.
[52] N. Milman,et al. Clinically overt hereditary hemochromatosis in Denmark 1948–1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients , 2001, Annals of Hematology.
[53] K. Hveem,et al. Screening for Hemochromatosis: High Prevalence and Low Morbidity in an Unselected Population of 65,238 Persons , 2001, Scandinavian journal of gastroenterology.
[54] M. Khoury,et al. Disease-related conditions in relatives of patients with hemochromatosis. , 2001, The New England journal of medicine.
[55] L. Grummer-Strawn,et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. , 2001, JAMA.
[56] R. Wolff,et al. HFE Genotype in Patients with Hemochromatosis and Other Liver Diseases , 2000, Annals of Internal Medicine.
[57] J. Olynyk,et al. A population-based study of the clinical expression of the hemochromatosis gene. , 1999, The New England journal of medicine.
[58] I. Fellows,et al. Haemochromatosis gene C282Y homozygotes in an elderly male population , 1999, The Lancet.
[59] M. O'Leary,et al. Prevalence of Hereditary Hemochromatosis in 16 031 Primary Care Patients , 1998, Annals of Internal Medicine.
[60] C. Frampton,et al. The significance of haemochromatosis gene mutations in the general population: implications for screening , 1998 .
[61] D. Häussinger,et al. Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.
[62] S. Fargion,et al. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis , 1994, Hepatology.
[63] B. Cesana,et al. Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis , 1992, Hepatology.
[64] A. Bomford,et al. Long term results of venesection therapy in idiopathic haemochromatosis. , 1976, The Quarterly journal of medicine.
[65] J. Stockman. Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome , 2013 .
[66] Brian K. Crownover,et al. Hereditary hemochromatosis. , 2013, American family physician.
[67] M. Khoury,et al. Evaluation of the validity and utility of genetic testing for rare diseases. , 2010, Advances in experimental medicine and biology.
[68] J. Stockman. Iron-Overload–Related Disease in HFE Hereditary Hemochromatosis , 2009 .
[69] Zentrum München. Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics , 2009 .
[70] D. Reboussin,et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[71] Jeffrey R. Botkin,et al. Summary of Recommendations: The Evaluation of Genomic Applications , 2022 .